News

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as

If you're looking for growth stocks that could make dramatic gains in a short amount of time, the healthcare sector has you covered. Recently, investment bank analysts have been pounding the table

Numerous companies in the healthcare sector are feverishly busy developing obesity drugs, as these products have taken the medical world by storm. One of the more prominent developers

Nvidia (NASDAQ: NVDA) closed at $180.12, down 0.82%. Trading volume surged to 278 million shares, well above the 178 million three-month average. The chipmaker, valued at $4.4 trillion, traded as

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), IREN (NASDAQ: IREN), Advanced Micro Devices (NASDAQ: AMD), and other semiconductor stocks. To learn more, check out the

Michael Burry is best known as one of the earliest and most vocal investors to predict the housing collapse of 2008 -- a prescient call that earned him notoriety and a Hollywood portrayal by

The healthcare industry is a good place to look for strong dividend-paying stocks. Many companies in the sector offer products that are consistently in demand, regardless of the state of the

Agilent Technologies (NYSE:A), a global leader in laboratory instruments and scientific solutions for life sciences and diagnostics, released its Q3 fiscal 2025 results on Aug. 27, 2025. The company

Veeva Systems(NYSE:VEEV) reported fiscal second quarter 2026 results on August 27, 2025, delivering $789 million in revenue and raising full-year billings guidance by $35 million. The quarter

Agilent Technologies(NYSE:A) reported Q3 FY2025 revenue of $1.74 billion, up 6.1% year-over-year on a core basis, with non-GAAP EPS of $1.37, both exceeding guidance. The company raised its

Shares of EchoStar (NASDAQ: SATS) jumped on Wednesday, closing the day up 15.5%. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both ticked up

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other semiconductor stocks. To learn more, check out the short video, consider

This year has offered no shortage of market-moving headlines shaping investor sentiment. Mixed job reports, new tariffs fueling turbulence in U.S. trade policy, and ongoing uncertainty around

Viking Therapeutics (NASDAQ: VKTX) announced trial results for its weight loss pill that disappointed stock market investors.

*Stock prices used were the afternoon prices of Aug. 24, 2025. The

Telecom giant AT&T (NYSE: T) struck a deal with EchoStar on Tuesday to acquire wireless spectrum licenses that cover nearly ever market across the U.S. The company will pay $23 billion for 30 MHz of

U.S. equity markets rose broadly on Tuesday as optimism over monetary policy, upbeat corporate news, and anticipation of Nvidia (NASDAQ: NVDA)'s earnings propelled gains. The S&P 500 added 0.41%

When it comes to growth stocks, you have to understand the risks going in. But there are three growth stocks that I have strong convictions about, and they could produce huge returns for investors.

Viking Therapeutics (NASDAQ: VKTX) delivered one of the most anticipated obesity readouts of the year -- and Wall Street promptly panicked. Shares plummeted 40% after the company released Phase 2

Dividend investing can be tricky, since income-focused investors want to find high yields while also avoiding stocks that end up cutting their quarterly payouts. There's a balance that has to be

Vertex Pharmaceuticals (NASDAQ: VRTX) is usually a market-beater, but it hasn't been so over the past year. The company's shares are down 18% over the trailing-12-month period due to a combination

Dividend stocks aren't all created equal. Some decrease their payouts, or suspend them altogether, when they face headwinds. Others have much stronger businesses and continue to raise their

Viking Therapeutics (NASDAQ: VKTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the